Back

Cost-effectiveness of a cardiovascular polypill strategy (aspirin, atorvastatin, ramipril) for the secondary prevention of cardiovascular disease based on real life improvement in risk factor control

17 April 2021 (08:00 - 08:09)
Organised by:
Congress Presentation Part of: Rapid fire abstracts - Secondary Prevention and Rehabilitation Health Economics EAPC Premium Access ESC Preventive Cardiology 2021

About the speaker

Photo
Mr Gabriel Rubio

Ferrer Internacional, Barcelona (Spain)

4 More presentations in this session

Presentation thumbnail
Cardiac rehabilitation is associated with lower 1-year all-cause mortality in primary pulmonary hypertension
Mr G. Kleinnibbelink (Nijmegen, NL)
Abstract Slides Video
Presentation thumbnail
Associations of severity of liver damages with physical function and prognosis in patients with heart failure
Mr T. Noda (Suita, JP)
Abstract Slides Video
Presentation thumbnail
Association of type 2 diabetes mellitus and mortality after coronary artery bypass graft surgery- a meta analysis
Ms A. Abdul Razzack (Hyderabad, IN)
Abstract Slides Video
Presentation thumbnail
How consistent are cost-effectiveness estimates of a cardiovascular polypill strategy for the secondary prevention of cardiovascular disease across different cardiovascular risk equations?
Mr D. Carcedo (Barcelona, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Rapid fire abstracts - Secondary Prevention and Rehabilitation

The Event

Event poster

ESC Preventive Cardiology 2021

17 April 2021 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Cost-effectiveness of HerzMobil Tirol, a multidimensional post-discharge disease management program for heart failure patients Economic evaluation along a one-year observation period
thumbnail
Congress Presentation
Newcard telemonitoring system improves survival at a lower cost than traditional approaches in chronic heart failure patients as assessed by data extract from the French National Health Data System
thumbnail
Congress Presentation
The cost-effectiveness of a digitally enabled telerehabilitation program delivered nationally to patients in Australia

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources